![]() | David Araújo‐VilarUETeM-Molecular Pathology Group. Department of Psychiatry, Radiology, Public Health, Nursing and Medicine, IDIS-CIMUS, University of Santiago de Compostela, Spain; ... |
KOL Resume for David Araújo‐Vilar
Year | |
---|---|
2022 | UETeM-Molecular Pathology Group. Department of Psychiatry, Radiology, Public Health, Nursing and Medicine, IDIS-CIMUS, University of Santiago de Compostela, Spain; Division of Endocrinology and Nutrition, University Clinical Hospital of Santiago de Compostela, 15706, Santiago de Compostela, Spain |
2021 | UETeM-Molecular Pathology Group, Department of Psychiatry, Radiology, Public Health, Nursing and Medicine, IDIS-CIMUS, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain;, (S.S.-I.);, (A.F.-P.);, (S.C.-G.);, (Á.H.-A.) Division of Endocrinology and Nutrition, University Clinical Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain |
2020 | Endocrinology and Nutrition Division, Complexo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain |
2019 | Department of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain |
2018 | UETeM-Molecular Pathology Group. Department of Medicine, IDIS-CIMUS, University of Santiago de Compostela, Spain |
2017 | Department of Medicine, UETeM, CIMUS School of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain. University of Santiago de Compostela UETeM‐Molecular Pathology Group Santiago de Compostela Spain |
2016 | Complexo Hospitalario de Santiago de Compostela, University of Santiago, Santiago, Spain |
2015 | Servicio de Endocrinoloxía e Nutrición, Complexo Hospitalario Universitario de Santiago de Compostela, Departamento de Medicina, Instituto de Investigaciones Sanitarias de Santiago-Universidade de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain |
2014 | Servicio de Endocrinoloxía e Nutrición, Complexo Hospitalario Universitario de Santiago de Compostela, Departamento de Medicina, Instituto de Investigaciones Sanitarias de Santiago-Universidade de Santiago de Compostela, Santiago de Compostela, A Coruña, España UETeM-Molecular Pathology Group, Department of Medicine, IDIS-CIMUS-Facultade de Medicina, University of Santiago de Compostela, Avda de Barcelona s/n, 15707 Santiago de Compostela, Spain |
2013 | Department of Medicine, School of Medicine and CIMUS Biomedical Research Institute, University of Santiago de Compostela-IDIS, Santiago de Compostela, Spain |
2012 | Division of Endocrinology and Nutrition, Hospital Clínico Universitario de Santuago de Compostela, Tv Choupana s/n, 15706 Santiago de Compostela, Spain Thyroid and Metabolic Diseases Unit (U.E.T.eM.), Department of Medicine, University of Santiago de Compostela |
2010 | Servicio de Endocrinoloxía e Nutrición, Complexo Hospitalario Universitario de Santiago de Compostela, Spain |
2008 | University Clinical Hospital of Santiago de Compostela |
2007 | Unidade de Enfermedades Tiroideas e Metabólicas (F.P., D.A.-V., O.P.-G., L.D.-G., J.L.-A.), Molecular Medicine Unit, Complejo Hospitalario Universitario de Santiago, Servicio Galego de Saude, University of Santiago de Compostela, Santiago de Compostela 15075, Spain |
2006 | Departamento de Medicina, |
2004 | Division of Endocrinology and Nutrition, Hospital Clı́nico Universitario de Santiago, Department of Medicine, School of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain |
2003 | Servicio de Endocrinoloxía e Nutrición, Departamento de Medicina, University of Santiago de Compostela, Spain. Division Of Endocrinology and Nutrition, Hospital Clínico Universitario de Santiago de Compostela, Department of Medicine, School of Medicine, University of Santiago de Compostela, and |
1999 | Service of Endocrinology and Nutrition and the Department of Medicine, Complejo Hospitalario Universitario de Santiago de Compostela, School of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain |
1998 | Service of Endocrinology and Nutrition, Complejo Hospitalario Universitario de Santiago, School of Medicine, University of Santiago de Compostela, r/Galeras s/n, 15705 Santiago de Compostela, Spain |
1997 | Sheikh Rashid Diabetes Unit, Radcliffe Infirmary, Oxford, UK Endocrinology Service of the University Hospital, School of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain |
David Araújo‐Vilar: Influence Statistics
Concept | World rank |
---|---|
bscl2 transcript | #2 |
Open the FULL List in Excel | |
Prominent publications by David Araújo‐Vilar
OBJECTIVE: Toxic thyroid adenoma (TA) is a common cause of hyperthyroidism. Mutations in the TSH receptor (TSHR) gene, and less frequently in the adenylate cyclase-stimulating G alpha protein (GNAS) gene, are well established causes of TA in Europe. However, genetic causes of TA remain unknown in a small percentage of cases. We report the first study to investigate mutations in TSHR, GNAS, protein kinase, cAMP-dependent, regulatory, type I alpha (PRKAR1A) and RAS genes, in a large series ...
Known for Toxic Thyroid | Mutations Tshr | Gnas Gene | Protein Kinase | Tsh Receptor |
CONTEXT: Steroid 11beta-hydroxylase (CYP11B1) deficiency (11OHD) is the second most common form of congenital adrenal hyperplasia (CAH). Cases of nonclassic 11OHD are rare compared with the incidence of nonclassic 21-hydroxylase deficiency.
OBJECTIVE: The aim of the study was to analyze the functional consequences of seven novel CYP11B1 mutations (p.M88I, p.W116G, p.P159L, p.A165D, p.K254_A259del, p.R366C, p.T401A) found in three patients with classic 11OHD, two patients with nonclassic ...
Known for Functional Consequences | Cyp11b1 Mutations | Nonclassic 11ohd | Hydroxylase Deficiency | Common Form |
Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy
[ PUBLICATION ]
PurposeThe purpose of this study is to summarize the effectiveness and safety of metreleptin in patients with congenital or acquired generalized lipodystrophy.MethodsPatients (n = 66) aged ≥6 months had lipodystrophy, low circulating leptin, and ≥1 metabolic abnormality (diabetes mellitus, insulin resistance, or hypertriglyceridemia). Metreleptin dose (once or twice daily) was titrated to a mean dose of 0.10 mg/kg/day with a maximum of 0.24 mg/kg/day. Means and changes from baseline to ...
Known for Generalized Lipodystrophy | Tgs Month | Metreleptin Patients | Liver Volume | Decrease Hba1c |
BACKGROUND: Lipodystrophies are a heterogeneous group of diseases characterized by abnormal fat distribution. Familial partial lipodystrophy 2 (FPLD2) is due to mutations in the LMNA gene. Previous studies have suggested that LMNA mutations 5' to the nuclear localization signal (NLS) are more likely to underlie laminopathies with cardiac or skeletal muscle involvement, while mutations 3' to the NLS are more likely to underlie lipodystrophy and progeroid syndromes.
OBJECTIVE: To study the ...
Known for Lmna Gene | Insulin Resistance | Partial Lipodystrophy | Hypertrophic Cardiomyopathy | Body Composition |
Influence of moderate physical exercise on insulin-mediated and non—insulin-mediated glucose uptake in healthy subjects
[ PUBLICATION ]
To establish the relative importance of insulin sensitivity and glucose effectiveness during exercise using Bergman's minimal model, 12 nontrained healthy subjects were studied at rest and during 95 minutes of moderate exercise (50% maximum oxygen consumption [VO2max]). Each subject underwent two frequently sampled intravenous glucose tolerance tests (FSIGTs) for 90 minutes, at rest (FSIGTr) and during exercise (FSIGTe). Plasma glucose, insulin, and C-peptide were determined. Insulin ...
Known for Glucose Effectiveness | Insulin Sensitivity | Bergmans Minimal Model | Tolerance Test | Adult Blood |
Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy
[ PUBLICATION ]
PurposeTo evaluate the effects of metreleptin in patients with partial lipodystrophy (PL).MethodsPatients aged ≥ 6 months with PL, circulating leptin < 12.0 ng/mL, and diabetes mellitus, insulin resistance, or hypertriglyceridemia received metreleptin doses (once or twice daily) titrated to a mean of 0.124 mg/kg/day. Changes from baseline to month 12 in glycated hemoglobin (HbA1c) and fasting serum triglycerides (TGs; co-primary endpoints), fasting plasma glucose (FPG), and liver volume ...
Known for Partial Lipodystrophy | Metreleptin Patients | Insulin Resistance | Hba1c Fasting | Primary Endpoints |
Familial partial lipodystrophy are Mendelian disorders involving abnormal body fat distribution and insulin resistance. The current classification includes the Köbberling syndrome (type 1 familial partial lipodystrophy), characterized by fat loss in the lower limbs and abnormal fat accumulation in other areas. Type 1 familial partial lipodystrophy appears to be heritable, but little is known about it, including putative contributing mutations. We aimed to characterize this syndrome ...
Known for Partial Lipodystrophy | Insulin Resistance | Lower Limbs | Type 1 | Fat Loss |
BACKGROUND: Type 2 familial partial lipodystrophy (FPLD2) is characterised by loss of fat in the limbs and buttocks and results from mutations in the LMNA gene.
AIM: To evaluate the role of several genes involved in adipogenesis in order to better understand the underlying mechanisms of regional loss of subcutaneous adipose tissue (scAT) in patients with FPLD2.
METHODS: In total, 7 patients with FPLD2 and 10 healthy control participants were studied. A minimal model was used to calculate ...
Known for Subcutaneous Adipose Tissue | Familial Partial | Type 2 | Lmna Gene | Insulin Sensitivity |
The effects of the acute insulin response to glucose (AIRg), insulin sensitivity (SI), and glucose effectiveness at zero insulin (GEZI) on intravenous glucose tolerance were studied in 94 non elderly healthy subjects with a wide range of body mass index (BMI). Conrad's coefficient of glucose assimilation (KG) was calculated between 10 and 19 minutes of an intravenous glucose tolerance test. Both SI and GEZI were estimated using Bergman's minimal model. AIRg was calculated as the area ...
Known for Intravenous Glucose | Acute Insulin Response | Insulin Sensitivity | Body Mass Bmi | 10 Minutes |
The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.
[ PUBLICATION ]
OBJECTIVE: Lipodystrophy syndromes are extremely rare disorders of deficient body fat associated with potentially serious metabolic complications, including diabetes, hypertriglyceridemia, and steatohepatitis. Due to their rarity, most clinicians are not familiar with their diagnosis and management. This practice guideline summarizes the diagnosis and management of lipodystrophy syndromes not associated with HIV or injectable drugs.
PARTICIPANTS: Seventeen participants were nominated by ...
Known for Lipodystrophy Syndromes | Practice Guideline | Metabolic Complications | Diagnosis Management | Genetic Testing |
High variability in CYP21A2 mutated alleles in Spanish 21‐hydroxylase deficiency patients, six novel mutations and a founder effect
[ PUBLICATION ]
OBJECTIVE: To detect common as well as rare and novel CYP21A mutations in 21-hydroxylase deficiency patients. To estimate the distribution of mutations and compare them with other European studies. To construct haplotypes linked to a recurrent novel mutation.
DESIGN: Genetic analysis by sequencing the entire CYP21A2 gene plus Southern blot.
PATIENTS: A total of 138 unrelated Spanish patients: 122 nonclassical forms (NCF) and 16 classical forms (CF) were studied.
RESULTS: Among the 266 ...
Known for Mutated Alleles | Gene Frequency | Southern Blot | Single Nucleotide | 21 Hydroxylase |
To evaluate the factors that determine the worsening of intravenous glucose tolerance in subjects at high risk for developing non-insulin-dependent diabetes mellitus (NIDDM), 15 glucose-tolerant offspring of NIDDM patients and 21 control subjects were studied. Each subject underwent a frequently sampled intravenous glucose tolerance (FSIGT) test. The intravenous glucose tolerance index (K(G) index) was calculated between minutes 10 and 40 of a FSIGT test. Insulin sensitivity (S(I)), ...
Known for Insulin Sensitivity | Glucose Effectiveness | Diabetes Mellitus | Tolerance Test | Crosssectional Study |
The objective of our research was to identify the mathematical model that would best define the relationship between obesity, insulin resistance (IR), and beta-cell function. Eighty-seven healthy subjects with a wide range of body mass index (BMI) were studied. Insulin sensitivity (IS) was calculated using Bergman's minimal model. Acute insulin response (AIRg) was calculated as the secretion of insulin during the first 10 minutes following a glucose bolus. IS x AIRg was used as an index ...
Known for Insulin Resistance | Minimal Model | Body Mass Bmi | Cell Function | Crosssectional Study |
AimLipodystrophy syndromes are rare heterogeneous disorders characterized by deficiency of adipose tissue, usually a decrease in leptin levels and, frequently, severe metabolic abnormalities including diabetes mellitus and dyslipidemia.PurposeTo describe the clinical presentation of known types of lipodystrophy, and suggest specific steps to recognize, diagnose and treat lipodystrophy in the clinical setting.MethodsBased on literature and in our own experience, we propose a stepwise ...
Known for Patients Lipodystrophy | Adipose Tissue | Replacement Therapy Complications | Diabetes Mellitus | Fat Loss |
LMNA missense mutations causing familial partial lipodystrophy do not lead to an accumulation of prelamin A
[ PUBLICATION ]
A variety of missense mutations in LMNA (the gene for lamin C and prelamin A) cause familial partial lipodystrophy (FPLD), a disease associated with reduced adipose tissue, particularly in the limbs. Several studies have reported that fibroblasts from FPLD subjects have an accumulation of prelamin A. Those findings were intriguing but also perplexing because many of the LMNA missense mutations associated with lipodystrophy are located in sequences distant from the sequences required for ...
Known for Lmna Mutations | Partial Lipodystrophy | Lamin Type | Lead Accumulation | Adipose Tissue |
Key People For Adipose Tissue
David Araújo‐Vilar:Expert Impact
Concepts for whichDavid Araújo‐Vilarhas direct influence:Adipose tissue, Insulin resistance, Partial lipodystrophy, Familial partial, Minimal model, Lmna gene, Lipodystrophy syndromes, Generalized lipodystrophy.
David Araújo‐Vilar:KOL impact
Concepts related to the work of other authors for whichfor which David Araújo‐Vilar has influence:Insulin resistance, Adipose tissue, Partial lipodystrophy, Congenital adrenal hyperplasia, Glucose effectiveness, Lmna gene, Pendred syndrome.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |